Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress

Core Insights - Acrivon Therapeutics is hosting a KOL panel on February 27, 2026, to discuss the ACR-368 registrational-intent trial results for endometrial cancer, highlighting the high unmet need in this area [1][2] - The panel will feature prominent experts in gynecological oncology, including Dr. Panos Konstantinopoulos, who will present late-breaking clinical data on ACR-368 at the ESGO Congress [2][5] Company Overview - Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision medicine through its proprietary Generative Phosphoproteomics AP3 platform, which enables unbiased interpretation of drug-regulated pathway activity [4] - The AP3 platform includes tools for data analysis and generative AI, allowing for rapid and actionable insights in drug discovery [4] Clinical Development - Acrivon is advancing ACR-368 (prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a Phase 2 trial for endometrial cancer, with Fast Track designation from the FDA [6] - The company is also developing ACR-2316, a selective WEE1/PKMYT1 inhibitor, which has shown promising initial clinical activity and a favorable tolerability profile in early trials [7] Upcoming Events - The live webcast of the KOL panel and presentation will be accessible through Acrivon's investor section on their website [3]